Pfizer starts human testing for experimental coronavirus vaccine in the US

Pfizer starts human testing for experimental coronavirus vaccine in the US
  • Pfizer hopes to produce “millions” of vaccines by the end of this year
  • Upon regulatory approval, Pfizer and BioNTech will work jointly to commercialize the vaccine worldwide.
  • The novel coronavirus has now killed at least 260,546 people across the world
  • Currently, there's no specific antiviral drug or vaccine available to treat or prevent COVID-19

 

Pfizer on tuesday started testing an experimental vaccine to combat the coronavirus in the United States.

The U.S.-based pharmaceutical giant, which is working alongside German drugmaker BioNTech, said the first human participants in the United States have been dosed with the potential vaccine, BNT162. They began human trials of the experimental vaccine late last month in Germany.

“With our unique and robust clinical study program underway, starting in Europe and now the U.S., we look forward to advancing quickly and collaboratively with our partners at BioNTech and regulatory authorities to bring a safe and efficacious vaccine to the patients who need it most,” Pfizer Chairman and CEO Albert Bourla said in a statement.

“The short, less than four-month time frame in which we’ve been able to move from preclinical studies to human testing, is extraordinary,” he added.

The experimental vaccine is composed of  genetic material called messenger RNA, or mRNA. The mRNA is a genetic code that tells cells what to build — in this case, an antigen that may induce an immune response for the virus.

The trial will test the experimental vaccine on adults ages 18 to 55 in the first stage before moving on to older groups, the company said, adding it hopes to test up to 360 people.

There are no FDA-approved therapies to treat Covid-19, and drugmakers are racing to produce a vaccine, which U.S. health officials say is expected to take at least 12 to 18 months.

The effort by Pfizer and BioNTech is one of several working on a potential vaccine to prevent Covid-19, which has sickened more than 3.5 million people worldwide and has killed at least 247,752 as of Monday night, according to data compiled by Johns Hopkins University. There were more than 100 vaccines in development globally as of April 30, according to the World Health Organization, with at least eight vaccine candidates already in human trials.

Waiting to get the Right vaccine is a futile attempt to contain COVID19

Hopes to get a vaccine to market are high, but scientists are setting expectations low for how quickly it can happen. Developing, testing and reviewing any potential vaccine is a long, complex and expensive endeavor that could take years, global health experts say.

The company said Tuesday it expects to increase to “hundreds of millions” of doses next year.